ANQ

TORONTO, Aug. 26, 2011 /CNW/ -- TORONTO, Aug. 26, 2011 /CNW/ - Allegiance Equity Corporation (TSXV: ANQ) The Board of Directors of the Corporation authorizes a private placement to raise $250,000 by sale of common shares to be priced within the context of the market. Allegiance has recently completed license and development agreements with extremely successful companies that have committed financial and other resources to marketing both CinGx(TM) and Relieva(TM). Allegiance requires interim funding to meet its ongoing operating and administrative costs until licensing revenues from are realized within the next several months. and to facilitate the further commercialization of Relieva(TM) and CinGx(TM). CinGx(TM) and Nealanders International Inc (Nealanders) Nealanders International - a world-class supplier of ingredients and additives in the food industry - has agreed to market and distribute CinGx(TM) in North America. CinGx(TM) is a revolutionary new product that helps prevent and treat Type 3 Diabetes. This proprietary food additive has a very compelling set of health benefits that enhance the value of most food and beverage products. Benefits include reducing blood sugar, cholesterol and triglycerides, while improving memory, cognitive function, energy and mental well-being. Recent research discovered that the brain produces insulin and depriving brain cells of insulin damages the cells, leading to memory loss, dementia, and Alzheimer's Disease. The impact of high blood glucose levels results in Type 3 Diabetes, also known as "brain diabetes." CinGx(TM) will greatly benefit the rapidly increasing number of North Americans diagnosed with diabetes, particularly Type 3 Diabetes. "Diabetes is one of the clear metabolic risk factors for Alzheimer's Disease (AD), perhaps through insulin signaling or secondary cardiovascular effects," says Dr. Cantillon, American Board Certified Neurologist and Psychiatrist. "After rosiglitazone and other failures, there are no metabolic treatments in sight for AD that are effective and/or do not have serious side effects. Therefore, insulin receptor protein tyrosine kinase treatment for Type 3 Diabetes might represent a new opportunity for long term safe prevention of AD." CinGx(TM) is a scientifically formulated and synergistic combination of standardized natural plant extracts that is both effective and safe. Nealanders is poised to market CinGx(TM) to its clients for placement in a variety of foods and beverages. Nealanders is in the process of completing regulatory documentation for compliance with Health Canada and the FDA requirements facilitate marketing CinGx(TM) to its clients. They have developed foods and beverages in numerous categories containing CinGx(TM) for presentation to their clients Neralanders and at SupplySide West, the world's largest event for healthy and innovative ingredients, a must-attend show for manufacturers, marketers and formulators of foods, beverages, supplements and cosmeceuticals. "Nealanders, the leading technology based ingredient company, has 2,000 customers in every corner of the industry, from nutrition, baking, confection, and food processing, to dairy, dry blending, pharmaceutical and more. They will maximize the commercialization of CinGx(TM) across a broad spectrum of mass market food products, says David Solomon, President of Allegiance Equity. ABOUT NEALANDERS Nealanders is recognized as the leader in the manufacturing and distribution of food ingredients, specializing in antioxidants, release agents, dough conditioners and enrichment blends. Proudly Canadian, Nealanders' Head Office is located in Mississauga, ON, with facilities strategically located across North America providing their customers with coast-to-coast coverage in both distribution and technical sales. On the leading edge of emerging trends and a strategic focus on wellness, Nealanders has extensive laboratory capabilities for product development and full technical and regulatory support. Nealanders embraces a customer focused mindset and value creation for their customers. "I am very excited about moving forward with this revolutionary new additive, says Steve Owen, VP Sourcing, Product Development & GM - Ontario. With the added value CinGx(TM) brings to our customers' products and the important health benefits for consumers, everybody wins." Relieva(TM )and Premier Selling Technologies Inc. (Premier) Prime Pharmaceutical Corporation (Prime) a subsidiary of Allegiance invented a patented extraction process which increases the concentration of the beneficial alkaloids from Mahonia Aquifolium by up to 75 times to create its proprietary extract Psorberine(TM) Prime licensed the worldwide rights to Relieva(TM) and Psorberine(TM) for online marketing to Premier Premier through its partner Yum Consumer Products (YCP) specializes in internet marketing via affiliate & direct Ad networks. YCP and its partner have generated over $500,000,000 in online product sales in the past 3 years. Relieva(TM) is made with Psorberine(TM) an anti-inflammatory, antibacterial product for the treatment of psoriasis and atopic dermatitis. Relieva(TM) provides immediate relief for itching, irritation and inflammation associated with almost all problem skin conditions with zero toxicity and irritation. Prime reaches Agreement with Collageena Skin Care (Collageena) for maketing and product development Prime reached an agreement on August 17(th) with Collageena Skin Care Products of Ottawa that provides for a joint venture for product development and worldwide, non-internet marketing of the Mahonia extract product line, both present and future products. The purpose of the agreement is to develop a dramatic new procedure for the treatment of numerous skin diseases utilizing Prime`s proprietary technology in combination with the technology and expertise of Collageena With Mahonia as a proven active ingredient, Prime possesses a patented extract with which the company plans to find innovative ways to help distinguish the company from the competition using our proprietary procedures for product application that increases   effectiveness penetration and bioavailabilty by 70%. Collageena has embarked on clinical trials for Relieva and hopes to have preliminary results in about a month. The combination of this unique application dramatically increases the effectiveness of Relieva and is a major breakthrough in the treatment of psoriasis and eczema. Collageena Skin Care Products specializes in Anti-aging products with an emphasis on Collagen stimulation both topically and internally. The company sells its products mainly through its specialized skin care clinics through its ever expanding network of distribution partners. Interest of Management Notice of Intention to Distribute Palm American Investments Inc. is the controlling shareholder of Allegiance holding 2,004,331 common shares. Palm American Investment Inc is controlled by David Solomon, Marilyn Bloovol and members of their family, Corporations controlled by Marilyn Bloovol and David Solomon, directors and officers of Allegiance may participate in the private placement, directly or indirectly through corporations controlled by them. Palm American filed a Notice of Intention on August 24th to sell up to 1,000,000 common shares in the market from time to time or by way of private sale There are presently 7,061921 common shares of Allegiance issued and outstanding. Additional information relevant to the Company's activities, including the Company's press releases can found on SEDAR at www.sedar.com THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY FOR HIS PRESS RELEASE, WHICH HAS BEEN PREPARED BY MANAGEMENT. To view this news release in HTML formatting, please use the following URL: http://www.newswire.ca/en/releases/archive/August2011/26/c6618.html p Allegiance Equity Corporationbr/ David Solomon br/ Presidentbr/ (416)  630 1221 br/ Email a href="mailto:dsolomon79@gmail.com" cr="true"dsolomon79@gmail.com/a /p

Copyright